 STOCKHOLM, Jan. 21, 2021 PRNewswire -- Calliditas Therapeutics AB publ Calliditas Nasdaq OMX: CALTX NASDAQ: CALT today announced that all 360 patients have been enrolled for the global Phase 3 clinical trial NefIgArd, which investigates the effect of Nefecon versus placebo in... 